Sign in

NCT06447207Active, not recruiting

Occupational Therapy Led Social Prescription for People With Parkinson Disease

Social Prescription for Loneliness in Community-based Group Exercise Classes for People With Parkinson Disease

Source: ClinicalTrials.gov · Last updated 3 Jun 2026

Brief summary (registry, in English)

Loneliness is an epidemic that the U.S. Surgeon General implored must be addressed by society as a whole. Increased loneliness (i.e., distressing feelings of isolation) in people with Parkinson's disease (PD) has a pervasive impact and is associated with worsened motor and non-motor symptoms, and quality of life. The investigators expect that individuals participating socially in the community would experience less loneliness. However, for individuals with PD participating in community-based group exercise programs, the investigators have found that over one third still report being lonely. Therefore, an evidence-based program needs to be added to address a significant problem of loneliness for people with PD-and occupational therapy is the leading discipline to add the intervention because social participation is one of eight occupations that an occupational therapist is focused on optimizing. The chief executive officer at the Parkinson Association of the Rockies (PAR), members of the Colorado State University Occupational Therapy Department, and members of the University of Colorado's Parkinson's Exercise Research Consortium have teamed up to address pervasive loneliness. Social prescription is a prime evidence-based intervention to add to existing PD community-based exercise classes because it has been shown to reduce loneliness. For this project, the investigators detect participants in the 'lonely' range through a standardized assessment. The investigators will work with PAR staff who will refer individuals identifying as 'lonely' to an occupational therapist, who will complete an individualized occupational profile and write the appropriate social prescription from 11 different interventions (examples include: intergenerational intervention, animal companions, physical activity, occupational therapy) from established community resources recommended for social prescription. The proposed project is designed with three primary goals: (1) determine the reach of the social prescription program, (2) evaluate the effectiveness of the program at one site, and (3) determine implementation strategies for scalability.

Status (registry)
Active, not recruiting
Study type
Interventional
Enrollment
40 (estimated)
First submitted
21 May 2024
Start date
13 Aug 2024
Primary completion date
30 Nov 2026
Lead sponsor
Colorado State University
NCT number
NCT06447207

What you commit to

  • Study type: Interventional
  • Planned participants: 40
  • From 13 Aug 2024 to the primary completion date, 30 Nov 2026
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • Have ever been diagnosed with dementia

Other

  • Not fluent in English

Who the study is looking for

  • At least 18 years old
  • Have a diagnosis of Parkinson Disease
  • Have participated in at least one exercise class or support group in the last year
  • Scored ≥5/9 on the UCLA 3-item Loneliness Scale during pre-screening
  • Agree to participate in a 6-month program including a social prescription and six visits with an occupational therapist or occupational therapy doctoral student

Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Save your city in your profile to sort them by distance.

SiteCityCountrySite status
Colorado State University
Coordinator of this site? Confirm its status
Fort CollinsUnited StatesUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.